不同强度阿托伐他汀钙对PCI术终点复合事件的影响研究

Influence of different intensity of atorvastatin in percutaneous coronary intervention(PCI) on terminal complex events

目的探讨不同强度阿托伐他汀钙对经皮冠状动脉介入术(PCI)患者终点复合事件的影响。方法将某院行PCI的冠心病患者246例随机分为高强度组和中强度组,高强度组患者给予阿托伐他汀钙40 mg/d口服,中强度组给予阿托伐他汀钙20 mg/d口服,观察各组患者血脂水平及终点复合事件情况。结果高强度组稳定型心绞痛及急性冠脉综合征患者LDL-C、HDL-C、TG及TC水平明显低于中强度组,两组分别比较差异具有统计学意义(P<0.05)。高强度组稳定型心绞痛患者复合终点事件与中强度组复合终点事件比较差异无统计学意义(P>0.05)。高强度组急性冠脉综合征患者复合终点事件明显低于中强度组,两组比较差异具有统计学意义(P<0.05)。中强度组局部肌肉疼痛伴肌酶升高4例(3.39%),高强度组12例(9.38%),两组比较差异具有统计学意义(P<0.05)。结论 PCI术后急性冠脉综合征患者接受高强度阿托伐他汀钙的获益更明显,而稳定型心绞痛患者接受高强度阿托伐他汀钙的获益不显著。

Objective To investigate the influence of different intensity of atorvastatin in percutaneous coronary intervention（PCI） on terminal complex events.Me thods 246 cases with PCI in our hospital were divided into the high intensity group and the moderate intensity group.The high intensity group were treated with atorvastatin（40 mg/d） orally and the moderate intensity group were given atorvastatin（20 mg/d） orally.The blood lipid level and terminal complex events were observed in both groups.Re s ults Levels of The LDL-C,HDL-C,TG and TC of patients with the stable angina pectoris and acute coronary syndrome in the high intensity group were lower than those in the moderate intensity group and the difference was statistically significant（ P〈0.05）.There was no significant difference on the terminal complex events in patients with stable angina pectoris between the high intensity group and the moderate intensity group（P〈0.05）.The terminal complex events of patients with acute coronary syndrome in the high intensity group were lower than those in the moderate intensity group and there was significant difference in them respectively（P〈0.05）.4 cases（3.39%） in the moderate intensity group and 12 cases（9.38%） in the high intensity group were reported with local muscle pain and increased muscle enzyme and there was significant difference between them（ P〈0.05）.Conclus ion The patients with acute coronary syndrome after PCI can get more benefits from a higher intensity of atorvastatin while the patients with stable angina pectoris get fewer benefits.